Autoimmune Diseases News

Autoimmune Diseases	Welcome, Profile Billing Logout

«1 2...109 110 111 112 113114115 116 117 118 119...156 157 »

||||||||||  opicinumab (BIIB033) / Biogen, Avonex (recombinant IFN-β-1a) / Biogen
Enrollment open:  SYNERGY: Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (clinicaltrials.gov) -  Nov 20, 2013
P2, N=396, Recruiting,  Sponsor: Biogen Idec
Not yet recruiting --> Recruiting

|||||||||| Trial termination: High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment (clinicaltrials.gov) - Nov 20, 2013
P2, N=1, Terminated, Sponsor: Seah Lim M.D.
Not yet recruiting --> Recruiting Recruiting --> Terminated; Insufficient accruals; PI leaving site

|||||||||| Enrollment change: High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment (clinicaltrials.gov) - Nov 20, 2013
P2, N=1, Terminated, Sponsor: Seah Lim M.D.
Recruiting --> Terminated; Insufficient accruals; PI leaving site N=50 --> 1

||||||||||  Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment open:  Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) -  Nov 20, 2013
P3, N=200, Recruiting,  Sponsor: Biogen Idec
N=50 --> 1 Not yet recruiting --> Recruiting

||||||||||  doxycycline / Generic mfg.
Trial completion:  Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy (clinicaltrials.gov) -  Nov 20, 2013
P1/2, N=14, Completed,  Sponsor: Sun Yat-sen University
Not yet recruiting --> Recruiting Recruiting --> Completed

|||||||||| Enrollment change: Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity (clinicaltrials.gov) - Nov 19, 2013
P2, N=7, Terminated, Sponsor: Bayer
Recruiting --> Completed N=50 --> 7

||||||||||  theralizumab (TAB08) / TheraMab
New P1/2 trial, PK/PD data:  Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 19, 2013
P1/2, N=18, Recruiting,  Sponsor: Theramab LLC

|||||||||| Enrollment change, Combination therapy: PSARA: Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=145, Completed, Sponsor: Revmatismesykehuset AS
N=50 --> 7 N=120 --> 145

|||||||||| Enrollment change: Insulin Delivery Using Microneedles in Type 1 Diabetes (clinicaltrials.gov) - Nov 19, 2013
P2/3, N=16, Completed, Sponsor: Emory University
N=120 --> 145 N=60 --> 16

|||||||||| Trial completion, Combination therapy: PSARA: Endothelial Function, Inflammatory Disease Activity, and Bone and Cartilage Markers in Rheumatic Patients: The Influence of Antirheumatic Treatment (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=145, Completed, Sponsor: Revmatismesykehuset AS
N=60 --> 16 Recruiting --> Completed

|||||||||| Trial completion: Insulin Delivery Using Microneedles in Type 1 Diabetes (clinicaltrials.gov) - Nov 19, 2013
P2/3, N=16, Completed, Sponsor: Emory University
Recruiting --> Completed Recruiting --> Completed

||||||||||  Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, HEOR:  Special Investigation in Patients With Rheumatoid Arthritis (Working Productivity Activity Impairment) (clinicaltrials.gov) -  Nov 18, 2013
P=N/A, N=2000, Active, not recruiting,  Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma, Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial:  A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. (clinicaltrials.gov) -  Nov 18, 2013
P3, N=100, Not yet recruiting,  Sponsor: Hoffmann-La Roche

||||||||||  Actemra SC (tocilizumab SC) / Roche, Halozyme
Trial initiation date:  COMP-ACT: A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX (clinicaltrials.gov) -  Nov 17, 2013
P3, N=600, Recruiting,  Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Jun 2013 --> Nov 2013

||||||||||  methylprednisolone oral / Generic mfg.
Clinical:  Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse (clinicaltrials.gov) -  Nov 17, 2013
P4, N=48, Recruiting,  Sponsor: Germans Trias i Pujol Hospital

||||||||||  Actemra SC (tocilizumab SC) / Roche, Halozyme
New P3 trial, Combination therapy, Monotherapy:  OSCAR: A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 17, 2013
P3, N=150, Recruiting,  Sponsor: Hoffmann-La Roche

||||||||||  Cinryze IV (C1 esterase inhibitor [human] IV) / Takeda
Trial completion:  C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation (clinicaltrials.gov) -  Nov 17, 2013
P1, N=10, Completed,  Sponsor: Michael Levy
Initiation date: Jun 2013 --> Nov 2013 Recruiting --> Completed

|||||||||| Trial completion: Coping Skills Training for Early Rheumatoid Arthritis (clinicaltrials.gov) - Nov 17, 2013
P=N/A, N=105, Completed, Sponsor: Duke University
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Enrollment open: Overnight Closed Loop Study in U.S. (clinicaltrials.gov) - Nov 17, 2013
P2, N=85, Recruiting, Sponsor: Medtronic Diabetes
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Simulect (basiliximab) / Novartis, Enbrel (etanercept) / Pfizer, Amgen, Zinbryta (daclizumab) / Biogen, AbbVie
Enrollment closed:  Efficacy of Islet After Kidney Transplantation (clinicaltrials.gov) -  Nov 17, 2013
P3, N=24, Active, not recruiting,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

||||||||||  Plivensia (sirukumab) / J&J
Trial completion:  A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 17, 2013
P1, N=12, Completed,  Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion:  A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment (clinicaltrials.gov) -  Nov 17, 2013
P2, N=48, Completed,  Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion:  To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 17, 2013
P3, N=89, Completed,  Sponsor: JW Pharmaceutical
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion: Morphometric Analysis of Orbital Structures in Graves´ Orbitopathy (clinicaltrials.gov) - Nov 16, 2013
P=N/A, N=80, Completed, Sponsor: University of Sao Paulo
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  insulin peglispro (LY2605541) / Eli Lilly
Enrollment open:  A Study of How Insulin Peglispro (LY2605541) and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics (clinicaltrials.gov) -  Nov 14, 2013
P1, N=32, Recruiting,  Sponsor: Eli Lilly and Company
Recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  otelixizumab (ChAglyCD3) / GSK
Trial termination:  Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 13, 2013
P1, N=40, Terminated,  Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; The risk-benefit ratio for patients has changed since we initiated the study, and that the study in its current form cannot be justified

||||||||||  Rituxan (rituximab) / Roche
Trial initiation date:  RAHIA: Rituximab in Auto-Immune Hemolytic Anemia (clinicaltrials.gov) -  Nov 13, 2013
P3, N=32, Recruiting,  Sponsor: Assistance Publique - H
Active, not recruiting --> Terminated; The risk-benefit ratio for patients has changed since we initiated the study, and that the study in its current form cannot be justified Initiation date: Sep 2010 --> Mar 2011

|||||||||| Enrollment change: Guidelines for Post-exercise Dietary Intake in T1DM (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=10, Completed, Sponsor: Northumbria University
Initiation date: Sep 2010 --> Mar 2011 N=19 --> 10

||||||||||  Orencia (abatacept) / BMS
Enrollment change, Head-to-Head:  Abatacept Versus Adalimumab Head-to-Head (clinicaltrials.gov) -  Nov 13, 2013
P3, N=869, Completed,  Sponsor: Bristol-Myers Squibb
N=19 --> 10 N=662 --> 869

|||||||||| Trial completion: Guidelines for Post-exercise Dietary Intake in T1DM (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=10, Completed, Sponsor: Northumbria University
N=662 --> 869 Recruiting --> Completed

||||||||||  Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed:  Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) -  Nov 12, 2013
P4, N=892, Active, not recruiting,  Sponsor: UCB Pharma SA
Recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Observational data:  An Observational Study on the Safety and Effectiveness of Rituximab in Patients With Severe Active Rheumatoid Arthritis (clinicaltrials.gov) -  Nov 12, 2013
P=N/A, N=1633, Active, not recruiting,  Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Trial withdrawal, Combination therapy:  A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs (clinicaltrials.gov) -  Nov 12, 2013
P4, N=0, Withdrawn,  Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Not yet recruiting --> Withdrawn

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment change, Combination therapy:  A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs (clinicaltrials.gov) -  Nov 12, 2013
P4, N=0, Withdrawn,  Sponsor: Hoffmann-La Roche
Not yet recruiting --> Withdrawn N=58 --> 0

||||||||||  plovamer (CO-14) / EMD Serono
Enrollment open:  EMR200575-001: Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) (clinicaltrials.gov) -  Nov 11, 2013
P2, N=550, Recruiting,  Sponsor: EMD Serono
N=58 --> 0 Not yet recruiting --> Recruiting

|||||||||| Enrollment open: The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS) (clinicaltrials.gov) - Nov 11, 2013
P=N/A, N=15, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

|||||||||| Enrollment closed: Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis (clinicaltrials.gov) - Nov 10, 2013
P3, N=161, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting

||||||||||  Extavia (IFN-β-1b) / Novartis
Enrollment change:  EPOC: A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) -  Nov 9, 2013
P4, N=1053, Completed,  Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting N=1473 --> 1053

||||||||||  Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J
Trial completion:  Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA) (clinicaltrials.gov) -  Nov 7, 2013
P3, N=436, Completed,  Sponsor: Janssen Biotech, Inc.
N=1473 --> 1053 Active, not recruiting --> Completed

||||||||||  Enbrel (etanercept) / Pfizer, Amgen
New P4 trial:  ANTIBODY-RA: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab (clinicaltrials.gov) -  Nov 7, 2013
P4, N=600, Recruiting,  Sponsor: Pfizer

|||||||||| Enrollment open: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - Nov 7, 2013
P1, N=64, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  Orencia (abatacept) / BMS
Enrollment open:  Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe (clinicaltrials.gov) -  Nov 7, 2013
P1, N=180, Recruiting,  Sponsor: Bristol-Myers Squibb
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  prednisone / Generic mfg.
Enrollment change:  EPITOME: Efficacy of Prednisone In the Treatment of Ocular Myasthenia (clinicaltrials.gov) -  Nov 6, 2013
P3, N=11, Terminated,  Sponsor: Michael Benatar
Not yet recruiting --> Recruiting N=88 --> 11

||||||||||  GSK2618960 / GSK
Trial termination:  A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) -  Nov 6, 2013
P1, N=16, Terminated,  Sponsor: GlaxoSmithKline
Recruiting --> Terminated; GSK confirmed misrepresentation of preclinical data that supported the rationale for GSK2618960 in MS. This decreased benefit assessment for MS

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Trial initiation date:  Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis (clinicaltrials.gov) -  Nov 6, 2013
P1/2, N=5, Recruiting,  Sponsor: Eric B. Suhler
This decreased benefit assessment for MS Initiation date: Jul 2013 --> Nov 2013

||||||||||  GSK2618960 / GSK
Enrollment change:  A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) -  Nov 6, 2013
P1, N=16, Terminated,  Sponsor: GlaxoSmithKline
Initiation date: Jul 2013 --> Nov 2013 N=68 --> 16

|||||||||| Preclinical: Detecting and Addressing Preclinical Disability (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=150, Recruiting, Sponsor: McMaster University

||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
Enrollment open:  Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis (clinicaltrials.gov) -  Nov 6, 2013
P1/2, N=5, Recruiting,  Sponsor: Eric B. Suhler
N=68 --> 16 Not yet recruiting --> Recruiting

|||||||||| Enrollment open, IO biomarker: Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=130, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting

||||||||||  Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
Trial completion:  RA-MOBILITY: Evaluation of Sarilumab (SAR153191/REGN88) on Top of Methotrexate in Rheumatoid Arthritis Patients (clinicaltrials.gov) -  Nov 6, 2013
P2/3, N=1594, Completed,  Sponsor: Sanofi
Not yet recruiting --> Recruiting Active, not recruiting --> Completed



	Diseases Companies Products Productz Mechanisms of Action Sites